To assess the effect of nifedipine dose on mortality and to review the potential mechanisms of such an effect.
Authors' conclusions
In patients with CHD, the use of short-acting nifedipine in moderate-to-high doses causes an increase in total mortality.
CRD commentary
There was little quality assessment of the included trials. Given the fact that the lower bound of the CI for the main effect is close to 1.0, it would have been useful to have examined the size and direction of the effect in a subset of the higher quality trials. However, the small number of RCTs may have precluded such an analysis. In this context the search strategy is important: no information is given as to what databases were searched, and a wider search may have produced a larger number of trials for analysis.
Implications of the review for practice and research
The effects of nifedipine on morbidity and mortality remain untested in hypertensive patients. In addition, the effects of using a beta-blocker in combination with a calcium antagonist need to be tested in large scale clinical trials to determine whether this could reduce the risk of mortality. 
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